Citadel Advisors’s Core Laboratories CLB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-23,000
Closed -$284K 12792
2025
Q3
$284K Sell
23,000
-36,300
-61% -$426K ﹤0.01% 10497
2025
Q2
$683K Buy
59,300
+47,900
+420% +$568K ﹤0.01% 7897
2025
Q1
$171K Buy
11,400
+900
+9% +$15.1K ﹤0.01% 10672
2024
Q4
$182K Sell
10,500
-700
-6% -$13.5K ﹤0.01% 10601
2024
Q3
$208K Buy
11,200
+4,700
+72% +$94.4K ﹤0.01% 10070
2024
Q2
$132K Sell
6,500
-9,200
-59% -$163K ﹤0.01% 10529
2024
Q1
$268K Sell
15,700
-7,000
-31% -$110K ﹤0.01% 9715
2023
Q4
$401K Buy
22,700
+12,100
+114% +$244K ﹤0.01% 8567
2023
Q3
$255K Buy
10,600
+7,200
+212% +$177K ﹤0.01% 9469
2023
Q2
$79K Sell
3,400
-2,800
-45% -$63.3K ﹤0.01% 11265
2023
Q1
$137K Sell
6,200
-14,900
-71% -$349K ﹤0.01% 10791
2022
Q4
$428K Buy
21,100
+6,100
+41% +$118K ﹤0.01% 8567
2022
Q3
$202K Sell
15,000
-8,300
-36% -$140K ﹤0.01% 10380
2022
Q2
$462K Buy
23,300
+11,900
+104% +$316K ﹤0.01% 8819
2022
Q1
$361K Sell
11,400
-2,200
-16% -$61.7K ﹤0.01% 10162
2021
Q4
$303K Sell
13,600
-5,900
-30% -$154K ﹤0.01% 10895
2021
Q3
$541K Buy
19,500
+3,100
+19% +$94.4K ﹤0.01% 9669
2021
Q2
$639K Buy
16,400
+8,200
+100% +$294K ﹤0.01% 9458
2021
Q1
$236K Sell
8,200
-20,300
-71% -$693K ﹤0.01% 11371
2020
Q4
$756K Buy
28,500
+500
+2% +$10.2K ﹤0.01% 7371
2020
Q3
$427K Buy
28,000
+3,100
+12% +$65K ﹤0.01% 7556
2020
Q2
$506K Buy
24,900
+6,800
+38% +$122K ﹤0.01% 7051
2020
Q1
$187K Sell
18,100
-49,100
-73% -$1.37M ﹤0.01% 8075
2019
Q4
$2.53M Buy
67,200
+8,000
+14% +$359K ﹤0.01% 4039
2019
Q3
$2.76M Sell
59,200
-46,700
-44% -$2.17M ﹤0.01% 3985
2019
Q2
$5.54M Buy
105,900
+75,100
+244% +$4.4M ﹤0.01% 2952
2019
Q1
$2.12M Buy
30,800
+9,800
+47% +$657K ﹤0.01% 4367
2018
Q4
$1.25M Sell
21,000
-3,000
-13% -$259K ﹤0.01% 4950
2018
Q3
$2.78M Sell
24,000
-19,100
-44% -$2.15M ﹤0.01% 3854
2018
Q2
$5.44M Buy
43,100
+23,300
+118% +$2.84M ﹤0.01% 2650
2018
Q1
$2.14M Buy
19,800
+10,300
+108% +$1.14M ﹤0.01% 3630
2017
Q4
$1.04M Sell
9,500
-12,500
-57% -$1.25M ﹤0.01% 4599
2017
Q3
$2.17M Buy
22,000
+4,200
+24% +$407K ﹤0.01% 3319
2017
Q2
$1.8M Buy
17,800
+10,000
+128% +$1.08M ﹤0.01% 3308
2017
Q1
$901K Sell
7,800
-10,200
-57% -$1.19M ﹤0.01% 4163
2016
Q4
$2.16M Sell
18,000
-1,200
-6% -$133K ﹤0.01% 2858
2016
Q3
$2.16M Sell
19,200
-16,100
-46% -$1.85M ﹤0.01% 2884
2016
Q2
$4.37M Sell
35,300
-10,100
-22% -$1.22M ﹤0.01% 1932
2016
Q1
$5.1M Buy
45,400
+24,300
+115% +$2.52M 0.01% 1753
2015
Q4
$2.29M Sell
21,100
-3,100
-13% -$355K ﹤0.01% 2595
2015
Q3
$2.42M Sell
24,200
-4,400
-15% -$479K ﹤0.01% 2715
2015
Q2
$3.26M Sell
28,600
-3,300
-10% -$400K ﹤0.01% 2500
2015
Q1
$3.33M Buy
31,900
+2,900
+10% +$309K ﹤0.01% 2468
2014
Q4
$3.49M Buy
29,000
+3,900
+16% +$512K ﹤0.01% 2322
2014
Q3
$3.67M Buy
25,100
+8,900
+55% +$1.37M ﹤0.01% 2263
2014
Q2
$2.71M Buy
16,200
+3,000
+23% +$534K ﹤0.01% 2446
2014
Q1
$2.62M Sell
13,200
-2,700
-17% -$510K ﹤0.01% 2377
2013
Q4
$3.04M Sell
15,900
-500
-3% -$93.1K ﹤0.01% 2132
2013
Q3
$2.77M Buy
16,400
+9,300
+131% +$1.44M ﹤0.01% 2096
2013
Q2
$1.08M Buy
+7,100
New +$1.01M ﹤0.01% 3122

Other funds holding CLB

Citadel Advisors's CLB Position: Q1 2026 in Review

Citadel Advisors increased its Core Laboratories (CLB) stake by 319% in Q1 2026, buying an estimated $2.11M and bringing the position to 154,800 shares worth $2.6M. The position accounts for ﹤0.01% of the portfolio, ranked #5541.

Citadel Advisors first reported a position in CLB in Q2 2013 and has held it in 46 quarters since. The position peaked at $44.3M in Q1 2019. 190 funds tracked by Wall St. Rank hold CLB as of Q1 2026.

  • Citadel Advisors held 154,800 shares of Core Laboratories worth $2.6M as of Q1 2026.
  • Citadel Advisors bought 117,867 Core Laboratories shares in Q1 2026, an estimated $2.11M.
  • Core Laboratories made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #5541 holding.
  • Citadel Advisors first reported a position in Core Laboratories in Q2 2013 and has held it in 46 quarters since.
  • Citadel Advisors's Core Laboratories position peaked at $44.3M in Q1 2019.
  • 190 funds tracked by Wall St. Rank held Core Laboratories as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.